Pr. Stanislas Lyonnet
Gene addition and genome editing approaches are currently under evaluation for the treatment of numerous genetic diseases. Evaluation of the safety of both these approaches is mandatory for the clinical translation of these therapeutic strategies. Thus, the acquisition of a new generation sequencer will allows to the evaluation of the integration site profile of lentiviral vectors carrying a therapeutic transgene as well as the potential off-target activity of the CRISPR/Cas9 genome editing system.
DIM, Institut Imagine